CD20 antibody is associated with worse COVID-19 outcomes for patients with MS

Dr Steve Simpson-Yap presents in this MEDtalk data from the largest international cohort of people with MS and COVID-19. The study shows that CD20 antibody treatment may be a risk factor for more severe COVID-19 disease among MS patients.